STRATEC

STRATEC has sold its subsidiary Diatron to an Indian investor consortium (fixed purchase price €10.0m plus performance‑related components); the OEM business for molecular and immunodiagnostics remains with STRATEC. Diatron is expected to generate around €20.0m in revenue in 2026 and an adjusted EBIT of about −€10.0m; STRATEC will record non‑cash impairments of €44.1m in Q3 2026 and expects a negative deconsolidation effect of €4.0–9.0m in Q4. After adjustments, STRATEC expects currency‑adjusted revenue for 2026 to be stable to slightly up and an adjusted EBIT margin of 13.0–15.0%; the previously communicated mid‑term targets are being withdrawn and will be updated with the 2026 annual report. » Más en finanzen.net

Stratec, a developer and manufacturer of automation and diagnostic systems for in-vitro diagnostics, recorded a share-price gain of about 35% over the past three months. Management stresses that products are contractually secured for the next five years, meaning growth through 2030 is more firmly underpinned than current figures show. The focus is on the long-term outlook beyond 2026. » Más en finanzen.net

Ralf Leistner, member of the supervisory board of STRATEC SE, received a total of 29,556 shares of the company on 19 August 2026. The shares were transferred to him free of charge by Hermann Leistner and Doris Leistner as a gift. The transaction took place outside a trading venue and was published in accordance with reporting obligations. » Más en de.investing.com